Cargando…

Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)

Recent breakthrough therapies targeting androgen receptor signalling in castration resistant prostate cancer (CRPC) involve multifunctional androgen receptor (AR) blockade and exhaustive androgen deprivation. Nevertheless, limitations to an enduring effectiveness of new drugs are anticipated in resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bremmer, Felix, Jarry, Hubertus, Strauß, Arne, Behnes, Carl Ludwig, Trojan, Lutz, Thelen, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193971/ https://www.ncbi.nlm.nih.gov/pubmed/25332874 http://dx.doi.org/10.1186/2193-1801-3-574

Ejemplares similares

Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer
por: Gehrig, Julia, et al.
Publicado: (2017)

N-cadherin expression in malignant germ cell tumours of the testis
por: Bremmer, Felix, et al.
Publicado: (2012)

CK19 is a sensitive marker for yolk sac tumours of the testis
por: Bremmer, Felix, et al.
Publicado: (2015)

Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer
por: Bremmer, Felix, et al.
Publicado: (2018)

Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours
por: Bremmer, Felix, et al.
Publicado: (2015)

Leiomyoma of the tunica albuginea, a case report of a rare tumour of the testis and review of the literature
por: Bremmer, Felix, et al.
Publicado: (2012)

N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma
por: Behnes, Carl Ludwig, et al.
Publicado: (2012)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Primary bladder adenocarcinoma: Case report with long-term follow-up
por: Uhlig, Annemarie, et al.
Publicado: (2018)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

SUN-003 Targeting Androgen Receptor-CXCR7-MARK Signaling Axis in CRPC
por: Gritsina, Galina, et al.
Publicado: (2019)

Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases?
por: Leitsmann, Conrad, et al.
Publicado: (2019)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
por: Li, Yan, et al.
Publicado: (2022)

Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
por: Hoshi, Senji, et al.
Publicado: (2022)

Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC)
por: Humphreys, Michael R, et al.
Publicado: (2013)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy
por: Meller, B., et al.
Publicado: (2015)

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
por: Pastina, Ilaria, et al.
Publicado: (2010)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Sertoliform cystadenoma: a rare benign tumour of the rete testis
por: Bremmer, Felix, et al.
Publicado: (2013)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Gamat-Huber, Melissa, et al.
Publicado: (2020)

Molecular Interplay between AURKA and SPOP Dictates CRPC Pathogenesis via Androgen Receptor
por: Nikhil, Kumar, et al.
Publicado: (2020)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
por: Kawahara, Takashi, et al.
Publicado: (2012)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
por: Maity, Sankar N., et al.
Publicado: (2016)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
por: Teo, Min Yuen, et al.
Publicado: (2018)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
por: Nishimura, Kazuo, et al.
Publicado: (2022)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
por: Iguchi, Taro, et al.
Publicado: (2019)

13-year-old tuberous sclerosis patient with renal cell carcinoma associated with multiple renal angiomyolipomas developing multifocal micronodular pneumocyte hyperplasia
por: Behnes, Carl Ludwig, et al.
Publicado: (2013)

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions
por: Scott, Rodney J., et al.
Publicado: (2021)

ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
por: Choi, Jae Duck, et al.
Publicado: (2021)

CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting
por: Lu, Kai, et al.
Publicado: (2022)

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
por: Robinson, Jessica L.L., et al.
Publicado: (2013)

Hereditary papillary renal cell carcinoma primarily diagnosed in a cervical lymph node: a case report of a 30-year-old woman with multiple metastases
por: Behnes, Carl Ludwig, et al.
Publicado: (2013)

Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines
por: Bremmer, Felix, et al.
Publicado: (2019)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
por: Tan, Pui S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3qcf8jv0hnmihiqiuv8091pf8c